AESGP Meeting: Climate Inaction Could Cost Healthcare Companies 10-20% Operating Profit

Failing to take sufficient action on climate change could be a costly business for consumer health companies. However, the good news from the AESGP's 60th Annual Meeting in Brussels, Belgium, is that at least half of the cost of decarbonizing will be balanced by savings, according to Boston Consulting Group. And climate change adaption will present firms with a wide variety of opportunities for product innovation, IQVIA Consumer Health's Volker Spitzer tells delegates.

Boston Consulting Group's Miranda Hadfield • Source: AESGP

Risks relating to climate change and nature could wipe up to a fifth from healthcare firms’ operating profits unless they take adequate measures to reduce their impact on the environment, warns Boston Consulting Group.

“It's very important that you start thinking about where all these risks are, and that you really invest in decarbonizing your own business and adapting your operations and supply chain to the changing world,” urged BCG partner Miranda Hadfield, speaking at the 60th AESGP Annual Meeting in Brussels, Belgium.

[Sidebar#RS154709]

The good news, according to BCG’s analysis, is that it's possible to deliver about 50% of this decarbonization – now required by the EU Green Deal, and subject to public disclosure as part of the Corporate Sustainability Reporting Directive – at zero net cost. “This is because many of the things that you should be doing in your business immediately and with your suppliers are actually cost saving,” Hadfield explained.

Entering into collective green power purchase agreements with other OTC firms and imposing minimum sustainability targets on suppliers are two ways that consumer health companies are accelerating their net zero targets without breaking the bank, she continued.

“If you're not doing it for cost reasons, you should definitely be doing it for carbon reasons,” Hadfield added, noting the huge impact that the healthcare sector has on the environment – 2.4 gigatons of CO2 and equivalents per annum, or 4-5% of global emissions, which is higher than aviation.

Product Innovation

While acknowledging that the subject of climate change is “rather depressing,” IQVIA Consumer Health’s Volker Spitzer delivered some good news for industry. Climate change adaptation will create new spaces for product innovation, he claimed.

“Perhaps you have already noticed that warmer temperatures and higher CO2 levels lead to longer pollen seasons?” asked Spitzer, who is IQVIA Consumer Health’s vice president, global R&D/RWE services and thought leadership.

“In North America, the pollen season starts now 20 days earlier,” he explained, “and we have 21% more pollen in the air. That’s a really big impact. Increased humidity indoors will also lead to more dust and dust mites, leading to increases in other kinds of allergies.”

Although no direct cause-effect relationship can be attributed, Spitzer noted that there has been a 43% increase in the number of packs of anti-allergy drugs sold since 2014 in Europe.

Climate change, then, creates a need among consumers for new allergy solutions, he argued. Not just in terms of new drugs, perhaps via Rx-to-OTC switch, but also with regards to the wider ecosystem of allergy – improving air quality indoors and outdoors and supporting allergy sufferers with AI-powered pollen alert systems.

Cough, Cold & Flu

The prevalence of viral respiratory infections (VRIs), such as cough, cold and flu, is also impacted by average temperature rises, Spitzer said. Although more research is needed, warmer temperatures and altered precipitation shift VRI outbreaks to new regions and seasons, increasing their frequency and severity.

Volker Spitzer

Again, product sales indicate some kind of relationship between climate change and consumer demand. In 2022, when Europe experienced an unprecedented average warming of 2.3 °C above pre-industrial levels, cough, cold and respiratory remedies witnessed an all-time high demand compared to the previous 10 years.

Nutritional deficiency, even malnutrition, can also be connected to climate change related effects, Spitzer explained. “Elevated temperatures reduce yields of staple foods like rice and wheat and also impact their nutritional value, leading to malnutrition.”

Dietary Supplements

Nutritional dilution, which negatively impacts protein quality and therefore certain minerals such as zinc and iron, both very important for immune support, is also linked to CO2 levels, Spitzer continued. “So, we need to bring innovative and affordable supplements and fortified foods to the world, especially in developing countries.”

“When we look at sales of vitamin and mineral supplements across the Europe, Middle East and Africa (EMEA) and Asia-Pacific (APAC) regions, we see a significant growth of 22% over the last years.”

“Again, it's difficult to make this connection to the climate change, but consumers are already, let's say, in tune with using these products to support their health and I think in the future this will continue further.”

Mental Health

Mental health is another area that is very important in terms of global warming, Spitzer said, because the psychological effect of climate change is “really huge.” “It's not only the frequency of disasters that is leading to stress, anxiety and depression, but the uncertainties that climate change is introducing, especially for young people.”

Consumer health companies are well positioned to help, he argued, by providing accessible, effective and science-backed products. Digital products, like therapeutics which draw on cognitive behavior therapy to support mental health, are also gaining a foothold in the market. “I'm sure this will continue in the future,” he said. (Also see "Bayer CH Backs Digital Therapeutics With ‘Multimillion-Dollar’ Mahana Partnership" - HBW Insight, 25 August, 2023.)

Ultimately, sustainable product innovation is hugely important for the consumer health industry, Spitzer noted. “It's upstream and downstream. It's every element of your business, so you need to have a look at that.”

On Right Path

Spitzer ended his presentation with a quote from the World Health Organization: “Climate change is impacting human lives and health in a variety of ways. It threatens the essential ingredients of good health – clean air, safe drinking water, nutritious food supply and safe shelter – and has the potential to undermine decades of progress in global health.”

“So that's rather depressing,” he said. “But there are a lot of opportunities to work together on this. That’s why we're here, and I think we on the right path, and I’m looking forward to improving our environment together.”

Read further coverage of AESGP’s Annual Meeting in HBW Insight: here president Jonathan Workman delivers a rousing call to action, while here Perrigo and Amcor representatives discuss the push for recyclable packaging.

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from International

Different Name, Same Contamination, Recall Problems For US Homeopathic Nasal Spray Firm

Green Pharmaceuticals’ SnoreStop Nasal Spray, previously marketed as “NasoSpray,” still is available even though agency officials on multiple occasions for a month recommended a recall after an April inspection found “gross microbial contamination” in one lot.

Kratom Industry Argues FDA Wants To Label All Products As Adverse Events Without Evidence

 

Week after publishing safety alert about OPMS Black Liquid Kratom “linked to serious adverse health effects, including death,” FDA announced market research “to understand and characterize emergent risk/safety and perceived benefits reportedly linked to kratom and psychedelics.” But it withdrew the study 10 days later.

ACNU Switch And IND Exemption Final Rules Targeted For October In FDA Regulatory Goals

 

Semi-annual regulatory agenda of non-binding target dates also sets December goal for an NPRM to recognize N-acetyl-L-cysteine as a lawful dietary ingredient. Like IND exemptions rule, item on NAC included for first time in FDA’s list.

‘Inside Regulatory Affairs’ With Kenvue's Kevin Whelan

This HBW Insight series profiles regulatory affairs specialists working in or supporting the consumer health and beauty product industries. In this installment, we speak to Kenvue's Kevin Whelan.

More from Geography

Perrigo Securities Class-Action Settlement Awards Attorneys’ Fees, Expenses Lower Than Requested

 

Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.

Over The Counter: Exploring The Postbiotic Opportunity In Consumer Health, With Kerry’s Sonja Nodland

 
• By 

In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry. 

US FDA Adcomm Reform Ideas: Neutral Facilitator As Chair, Public Hearing Lottery Process Tweaks

 
• By 

Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.